Drugs That Affect Glutamate: How They Work and Are Used

Dozens of medications now in clinical use work by dialing glutamate signaling up or down in the brain. Glutamate is the nervous system’s primary excitatory chemical messenger, involved in everything from forming memories to processing pain, so drugs that target it have remarkably diverse uses: slowing cognitive decline in dementia, lifting treatment-resistant depression within hours, controlling seizures, easing chronic pain, and helping people stay sober after alcohol dependence. The pharmacology is more varied than most people realize, because glutamate operates through several distinct receptor types and recycling systems, each offering a different point of intervention.

Why Glutamate Matters So Much

Glutamate is the most abundant excitatory neurotransmitter in the mammalian brain. When a neuron releases it into the synapse, nearby neurons fire more readily. That basic process underlies learning, synaptic strengthening, and virtually every cognitive function you can name. But the brain has to keep glutamate levels tightly controlled, because too much of it is toxic. After glutamate does its job, support cells called astrocytes scoop it up and convert it into glutamine, which gets shuttled back to neurons and recycled into fresh glutamate. This cycle keeps concentrations in the safe zone under healthy conditions.

Glutamate acts on two broad families of receptors. The fast-acting ones, called ionotropic receptors, open ion channels directly when glutamate binds. The two most clinically important subtypes are NMDA receptors and AMPA receptors. A second family, the metabotropic glutamate receptors, triggers slower signaling cascades inside the cell rather than opening channels directly.¹ Nearly every drug discussed here targets one of these receptor types or the machinery that clears glutamate from the synapse.

What Happens When Glutamate Gets Out of Control

When glutamate floods the space between neurons and stays there too long, it overactivates receptors, especially NMDA receptors. Calcium pours into cells at rates they cannot handle. That triggers a chain of damage: mitochondria malfunction, free radicals accumulate, and neurons start to die.² This process, called excitotoxicity, plays a role in stroke, traumatic brain injury, and neurodegenerative diseases like Alzheimer’s and ALS. In stroke, the energy failure caused by blocked blood flow means cells can no longer pump glutamate out of the synapse, so levels spike and surrounding tissue gets caught in a wave of secondary damage.³

Understanding excitotoxicity is the key to understanding why so many glutamate-targeting drugs exist. The therapeutic goal is usually to dampen excessive signaling without shutting down the normal glutamate activity the brain needs for everyday function. That turns out to be a tricky balance, and different drugs solve it in very different ways.

Memantine and Alzheimer’s Disease

Memantine is probably the best-known drug designed to temper glutamate signaling. It is prescribed for moderate-to-severe Alzheimer’s disease, where chronic, low-level overactivation of NMDA receptors contributes to the progressive loss of neurons. The clever part of memantine’s design is that it preferentially blocks NMDA receptors only when they are excessively open. It sits in the channel at low affinity and leaves quickly, so it does not interfere much with the brief bursts of normal signaling that underlie learning and memory.⁴

In practice, memantine does not reverse Alzheimer’s. It modestly slows the worsening of symptoms, sometimes enough that patients can manage daily activities a bit longer. Doctors often combine it with cholinesterase inhibitors like donepezil, which work on a completely different neurotransmitter system. The combination addresses two separate aspects of the disease at once.

Ketamine and Fast-Acting Antidepressants

Ketamine has been used as an anesthetic since the 1960s, but its emergence as a rapid antidepressant in the early 2000s caught psychiatry off guard. Traditional antidepressants take weeks to work. Ketamine, given at sub-anesthetic doses by infusion, can produce noticeable relief from severe depression within hours. Its nasal-spray derivative, esketamine, received regulatory approval for treatment-resistant depression.

The mechanism is more complex than simple NMDA receptor blockade. When ketamine blocks NMDA receptors on certain inhibitory interneurons, the downstream effect is actually a burst of glutamate release that activates AMPA receptors. That AMPA activation triggers signaling pathways involved in growing new synaptic connections, including increased production of brain-derived neurotrophic factor (BDNF) and activation of a protein called mTOR.⁵ The result is a rapid strengthening of excitatory synapses that had weakened during depression.⁶ There is also evidence that an active metabolite of ketamine, hydroxynorketamine, contributes to the antidepressant effect through mechanisms that may not even require NMDA blockade at all.⁷

Ketamine’s success has reshaped how researchers think about depression. For decades, the dominant theory centered on serotonin deficiency. The glutamate story suggests that, at least for some patients, the core problem is a loss of synaptic connections in mood-regulating brain areas, and that restoring those connections produces faster relief than nudging serotonin levels ever could.

Riluzole and ALS

Riluzole was the first drug approved specifically for amyotrophic lateral sclerosis (ALS), and it remains one of very few treatments that slow the disease’s progression. Motor neurons in ALS are especially vulnerable to excitotoxic damage, so reducing glutamate activity at those cells is a logical therapeutic strategy. Riluzole works from multiple angles: it inhibits glutamate release from nerve terminals, partly by inactivating sodium channels on those terminals, and it also blocks NMDA receptors to some extent on the receiving side.⁸

The benefit is real but modest. Riluzole extends survival by several months on average, and it does not restore lost motor function. Still, in a disease with devastatingly few options, even a modest extension is meaningful, and riluzole’s mechanism helped confirm that glutamate excitotoxicity is part of what kills motor neurons in ALS.

Lamotrigine for Seizures and Bipolar Disorder

Lamotrigine is one of the most widely prescribed antiepileptic drugs and also a first-line treatment for preventing depressive episodes in bipolar disorder. Its primary mechanism involves blocking voltage-gated sodium channels, which stabilizes overexcitable neurons. But it also reduces glutamate release, and that anti-glutamate action likely contributes to its neuroprotective properties and its unusual effectiveness in mood stabilization.⁹

The dual utility of lamotrigine illustrates a broader pattern: drugs that reduce excessive glutamate signaling often turn out to be useful in more than one condition, because excitotoxicity and hyperexcitability show up across a range of neurological and psychiatric disorders.

Perampanel and AMPA Receptor Blockade

Most of the drugs discussed so far target NMDA receptors or glutamate release. Perampanel takes a different approach: it blocks AMPA receptors, the other major type of fast glutamate receptor. AMPA receptors mediate the bulk of moment-to-moment excitatory signaling, so blocking them is a powerful way to reduce neural excitability. Perampanel is the first selective, noncompetitive AMPA antagonist to reach the market and is approved for treating several types of seizures in patients aged 12 and older.¹⁰

Researchers are actively exploring perampanel beyond epilepsy. In animal studies, the drug reduced brain damage after experimental stroke and improved both motor function and later cognitive outcomes, likely through anti-inflammatory and antioxidant effects downstream of AMPA blockade.¹¹ Other conditions under investigation include brain-tumor-related epilepsy, status epilepticus, sleep disorders, and even some neurodegenerative diseases.¹² Whether those preclinical findings will translate into approved treatments is still uncertain, but the breadth of interest underscores how central AMPA receptors are to brain pathology.

Acamprosate and Alcohol Dependence

Chronic heavy drinking reshapes the brain’s balance between excitatory and inhibitory signaling. Alcohol suppresses glutamate activity, and over time the brain compensates by upregulating glutamate receptors and release. When someone stops drinking, that compensatory hyperexcitability is suddenly unopposed, producing the anxiety, irritability, and craving that drive relapse. Acamprosate, approved by the FDA for maintaining abstinence in alcohol dependence, works by dampening that glutamate overshoot.¹³

The drug modulates NMDA receptor transmission and decreases brain glutamate levels, while also having some indirect effects on inhibitory GABA signaling.¹⁴ In a controlled trial using brain imaging to measure glutamate directly, acamprosate produced a large reduction in central glutamate levels compared to placebo.¹⁵ The practical effect is that people taking acamprosate experience less of the neurological distress associated with early sobriety, which helps them avoid picking up a drink.

N-Acetylcysteine and Glutamate Transport

Not every glutamate-targeting intervention works at receptors. N-acetylcysteine (NAC) is an over-the-counter supplement best known as the antidote for acetaminophen overdose, but it also influences glutamate levels by restoring the function of a transporter called GLT-1. In animal models of cocaine addiction, NAC’s ability to reduce cue-triggered relapse depended specifically on restoring GLT-1 activity, which clears excess glutamate from the synapse.¹⁶

NAC has been studied in a wide range of psychiatric and neurological conditions, from obsessive-compulsive disorder to traumatic brain injury. Results are mixed and often preliminary, but the underlying idea is the same: if you can help the brain’s glutamate cleanup crew work more efficiently, you can reduce the excitotoxic background noise that contributes to many disorders. NAC’s safety profile and low cost make it an attractive candidate for further study, though the evidence is not yet strong enough for it to be considered a standard treatment for any psychiatric condition.

Boosting NMDA Function in Schizophrenia

While most glutamate drugs aim to reduce signaling, some conditions involve too little NMDA receptor activity. In schizophrenia, a body of research spanning over two decades points to NMDA receptor hypofunction as a key contributor, especially on certain inhibitory neurons in the cortex. When those NMDA receptors are underactive, the circuits that normally keep excitatory activity in check stop working properly, producing the disordered thinking, social withdrawal, and cognitive difficulties that characterize the illness.¹⁷¹⁸

This insight led to a strategy that is the opposite of most glutamate pharmacology: instead of blocking NMDA receptors, enhance them. NMDA receptors require a co-agonist, either glycine or D-serine, to fully activate. Agents like D-serine, glycine itself, and sarcosine (which blocks glycine reuptake, keeping more of it available) have shown the ability to improve symptoms in patients with chronic schizophrenia when added to standard antipsychotic treatment.¹⁹ Sarcosine in particular may enhance NMDA function through more than one mechanism: it both boosts glycine availability and acts as a co-agonist directly, producing effects that differ from glycine alone.²⁰

These approaches are still largely experimental and have not yet produced a blockbuster drug, but they represent one of the most active areas in schizophrenia research. Metabotropic glutamate receptors are also being explored as targets. Receptors such as mGluR2/3 and mGluR5 are found in brain regions critical for mood and cognition, and they are altered in schizophrenia, bipolar disorder, and depression, making them attractive targets for novel drugs.²¹

NMDA Receptors and Pain

Chronic pain involves its own form of glutamate excess. When pain signals fire repeatedly, NMDA receptors in the spinal cord undergo a process called central sensitization: they become easier to activate, so signals that should feel mild get amplified into intense pain. This is a major driver of neuropathic and inflammatory pain conditions. Blocking spinal NMDA receptors is a logical target, and in practice, sub-anesthetic ketamine infusions are used in some pain clinics for exactly this purpose. However, the side effects of NMDA blockade, including dissociation, dizziness, and cognitive effects, have limited how widely these drugs can be used for pain.

Researchers continue to look for NMDA-targeting pain drugs with fewer side effects, including agents that act at specific NMDA receptor subtypes or that target only the spinal cord rather than the whole brain. The gap between the clear role NMDA receptors play in central sensitization and the difficulty of safely targeting them in patients is one of the more frustrating bottlenecks in pain medicine.

Safety Tradeoffs of Blocking NMDA Receptors

A persistent challenge across glutamate pharmacology is that strong NMDA blockade comes with real risks. In humans, drugs like phencyclidine (PCP) and high-dose ketamine produce hallucinations and psychosis-like symptoms. In animal studies, NMDA antagonists can damage neurons in the cerebral cortex.²² This neurotoxic potential appears to vary with age and dose, and it is one reason why the safer, lower-affinity NMDA blockers like memantine were developed: by blocking the channel only weakly and briefly, memantine avoids the psychotomimetic and neurotoxic profile of more potent agents.²³

This safety profile is why you do not see powerful NMDA antagonists prescribed as daily pills. Ketamine infusions are given in controlled settings with monitoring. Memantine’s gentle pharmacology is what makes it safe enough for elderly dementia patients to take every day. The difference between a useful drug and a dangerous one, in this field, often comes down to how quickly the molecule leaves the receptor channel.

Does Dietary Glutamate Affect the Brain?

Given how central glutamate is to brain function, people understandably wonder whether eating it, most commonly as monosodium glutamate (MSG) in food, could affect neurological health. The short answer is no. Glutamate is metabolically compartmentalized in the body. Almost none of what you eat passes from the gut into the bloodstream in significant amounts, and essentially none crosses the blood-brain barrier to reach the brain.²⁴ The brain manufactures its own glutamate locally, primarily through the astrocyte recycling pathway.²⁵ So eating a bowl of food seasoned with MSG does not deliver a dose of neurotransmitter to your brain the way taking a pill of ketamine does. The drugs discussed in this article work because they are designed to cross the blood-brain barrier or are delivered directly into the bloodstream; dietary glutamate simply is not.

Glutamate’s Role in Shaping the Developing Brain

Beyond disease and drug therapy, glutamate signaling through NMDA receptors plays a fundamental role in brain development. During early life, the brain produces far more synaptic connections than it ultimately needs. A process of refinement follows, in which strong, useful connections are stabilized while weak or redundant ones are pruned away. NMDA receptors are essential gatekeepers for this process. In experiments where neurons lack NMDA receptors entirely, both the pruning of excess connections and the strengthening of the remaining ones are blocked.²⁶

This has practical implications for drug safety. Any drug that substantially blocks NMDA receptors during critical developmental windows, like the prenatal period or early childhood, carries theoretical risk to normal brain wiring. Anesthesiologists have paid close attention to this concern, since ketamine and other NMDA-blocking anesthetics are sometimes used in pediatric surgery. The evidence in humans is still debated, but preclinical findings are clear enough that regulatory agencies have flagged the issue. It is one more reason why glutamate drugs tend to be used cautiously and with clear clinical justification.

An Ancient Signaling System

One reason glutamate receptors are such rich drug targets is that they are deeply conserved in evolution. Genes encoding glutamate receptors are not unique to animals with complex brains. Molecular analysis has found glutamate receptor genes in plants, placing the origin of this signaling system before the evolutionary split between the plant and animal kingdoms.²⁷ In plants, these receptors participate in responses to stress and environmental signals rather than nerve impulses. The deep evolutionary roots mean that the basic architecture of glutamate receptors has been tuned by natural selection over an extraordinarily long time, producing a system that is both robust and, from a pharmacologist’s perspective, full of specific binding sites and regulatory mechanisms that drugs can exploit. That structural richness is exactly why the field keeps finding new therapeutic angles on a molecule the brain has been using since before brains existed.